• Exchange: NYSE MKT LLC
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharmaceuticals

Hemispherx Biopharma Inc

+ Add to Watchlist


0.2810 USD 0.0050 1.81%

As of 20:04:08 ET on 07/30/2014.

Snapshot for Hemispherx Biopharma Inc (HEB)

Open: 0.2800 Day's Range: 0.2716 - 0.2850 Volume: 658,930
Previous Close: 0.2760 52wk Range: 0.1900 - 0.5500 1-Yr Rtn: +22.17%

Stock Chart for HEB

No chart data available.
  • HEB:US 0.2810
  • 1D
  • 1M
  • 1Y
Interactive HEB Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for HEB

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.1000
Est. EPS (USD) (12/2014) -0.1100
Est. PEG Ratio -
Market Cap (M USD) 51.66
Shares Outstanding (M) 183.85
30 Day Average Volume 594,040
Price/Book (mrq) 1.6098
Price/Sale (ttm) 265.9224
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/08/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for HEB

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for HEB

Hemispherx Biopharma, Inc. is a biopharmaceutical company that focuses on the development of nucleic acids to enhance the natural anti-viral defense systems of the human body. The Company's lead product, Ampligen, is undergoing clinical trials for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

William A CarterChairman/Pres/CEO/CSOThomas K EquelsVice Chair/CFO/Secy/Gen Cnsl
David R StrayerChief Medical Ofcr/Medical DirAdam PascaleChief Acctg Officer/Controller
More Company Profile & Key Executives for HEB

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil